Listed

ARS Pharmaceuticals, Inc.: Form 10-Q for the period ended Jun 30, 2022

Filed with the SEC on Aug 11, 2022 and accepted by EDGAR at Aug 11, 2022, 16:03 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2022-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2022-04-01 to 2022-06-30$12.2mus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2022-01-01 to 2022-06-30$29.1mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2022-04-01 to 2022-06-30−$19.8mus-gaap:OperatingIncomeLoss
Operating income6 months2022-01-01 to 2022-06-30−$44.5mus-gaap:OperatingIncomeLoss
Net income3 months2022-04-01 to 2022-06-30−$19.4mus-gaap:NetIncomeLoss
Net income6 months2022-01-01 to 2022-06-30−$44.1mus-gaap:NetIncomeLoss
Operating cash flow6 months2022-01-01 to 2022-06-30−$34.9mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2022-01-01 to 2022-06-30$618.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2022-06-30$218.7mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2022-06-30$263.1mus-gaap:AssetsCurrent
Total assetsAt period end2022-06-30$294.0mus-gaap:Assets
Current liabilitiesAt period end2022-06-30$11.1mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2022-06-30$15.2mus-gaap:Liabilities
Shareholders' equityAt period end2022-06-30$278.8mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0000950170-22-016840. Last ingested by Listed: Nov 10, 2026, 04:18 ET. Listed shows no prices and gives no investment advice.